# Biologics

Biologics — monoclonal antibodies, ADCs, CAR-T and gene therapy — are the largest and fastest-growing drug class, built on a reproducible cell-line platform at 2–10 g/L titers.

Source: https://en.bioecon.ru/technology/biologics/
Updated: 2026-08-18



## Overview and value chain

Markers: [EC: ATMP Regulation (EC No 1394/2007) | OECD: Bio-Pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)]

Biologics are drugs produced by living systems: monoclonal antibodies (mAbs), antibody-drug
conjugates (ADCs), fragment and bispecific antibodies, and advanced ATMPs (CAR-T, gene therapy).
It is the largest drug class: a $400B+ global market, and biologics are >60% of big-pharma
pipelines. mAb production in CHO cell lines reaches 2–10 g/L titers in fed-batch, and the
platform (cell line → bioreactor → purification) is reproducible across molecules. ADCs and CAR-T
extend the platform into targeted oncology.

Key directions of biologics:
1. **Monoclonal antibodies (Monoclonal Antibodies):** blockers (Humira, Keytruda), bispecifics.
2. **Antibody-drug conjugates (Antibody-Drug Conjugates):** Enhertu; the Pfizer–Seagen $43B deal.
3. **CAR-T and cell therapy (CAR-T & Cell Therapy):** Kymriah, Yescarta; ~$400k per course.
4. **Gene therapy (Gene Therapy):** Zolgensma, Luxturna — single-dose treatment of inherited disease.

### Sectoral value chain

```
[cell line] ──> [upstream] ──> [purification] ──> [formulation]
                    │
              (CHO, 2–10 g/L titer)
                    │
                    ▼
[drug product] <─── [fill-finish] <─────┘
```

### Value chain levels

| Level | Description | Key inputs/outputs |
|:---|:---|:---|
| **Cell Line Development** | stable CHO line with the target transgene | **In:** vector, cells. **Out:** MCB/WCB. |
| **Upstream (Bioreactor)** | fed-batch/perfusion in bioreactors | **In:** media, feed, gases. **Out:** supernatant. |
| **Harvest & Clarification** | cell separation, depth filtration | **In:** supernatant. **Out:** liquor. |
| **Downstream Purification** | Protein A + ion-exchange chromatography, viral inactivation | **In:** liquor. **Out:** pure mAb. |
| **Formulation (UF/DF)** | ultrafiltration/diafiltration, standardization | **In:** pure mAb. **Out:** formulation. |
| **Aseptic Fill-Finish** | sterile fill, lyophilisation, labelling | **In:** formulation. **Out:** drug product (vial/syringe). |

Cross-cutting technologies of the sector:
- **CHO platform (CHO Platform):** 2–10 g/L titers, reproducible cell line across molecules.
- **Single-use bioprocess (Single-Use Bioprocessing):** disposable bags/bioreactors for flexibility.
- **High-throughput analytics (High-Throughput Analytics):** PAT, mass spectrometry, charge profiling.

---

## US

The US is the largest biologics market and leads on ATMP M&A and VC.

### MAb & ADC leadership, M&A consolidation, FDA
- **AbbVie / Amgen:** Humira (peak >$20B/year) and Enbrel; bispecifics.
- **Pfizer → Seagen ($43B):** consolidating ADC leadership.
- **FDA:** expedited pathways (Breakthrough, RMAT) for CAR-T and gene therapy.

---

## CN

China is rapidly scaling biomanufacturing capacity and a biosimilar portfolio.

### WuXi & biosimilar scale, NMPA pathway, capacity build-out
- **WuXi Biologics:** the largest biologics CRDMO platform.
- **Biosimilars:** mass production of domestic mAb biosimilars.
- **NMPA:** accelerated approval for strategically important molecules.

---

## EU

The EU is home to the largest biopharma giants and bioproduction-sovereignty programs.

### Roche/Novartis/Sanofi, France Bioproduction 2030, EMA ATMP
- **Roche/Novartis/Sanofi:** Herceptin, Kymriah, Dupixent — mAb/CAR-T/antibody flagships.
- **France "Bioproduction 2030":** mAb production localisation, flexible iFab mini-plants.
- **EMA ATMP:** strict regulation of CAR-T and gene therapy.

---

## Leading companies and research institutes

| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|:---|:---|:---|:---|:---|
| **Roche** | 🇨🇭 Switzerland | *Herceptin*, *Avastin*, *Rituxan* | CHO platform, Genentech | Commercial |
| **Novartis** | 🇨🇭 Switzerland | *Kymriah* (CAR-T), *Cosentyx* | first approved CAR-T | Commercial |
| **Sanofi** | 🇫🇷 France | *Dupixent*, *Sarclisa* | bispecific antibodies | Commercial |
| **AbbVie** | 🇺🇸 USA | *Humira*, *Skyrizi* | immunology mAbs | Commercial |
| **Amgen** | 🇺🇸 USA | *Enbrel*, biosimilars | large-scale platform | Commercial |
| **WuXi Biologics** | 🇨🇳 China | biologics CRDMO | bioproduction capacity | Commercial |

---

## Tech stack and innovations

The stack rests on the cell line, the bioreactor and deep purification.

1. **CHO platform (CHO Cell-Line Platform):**
   - fed-batch at 2–10 g/L titer; reproducible genetics across molecules.
   - case: Roche/Genentech — the benchmark large-scale mAb platform.
2. **Single-use bioprocess (Single-Use Bioprocessing):**
   - disposable bioreactors and bags cut capex and cross-contamination.
3. **ADC conjugation (ADC Conjugation):**
   - linker-payload chemistry for targeted cytotoxic delivery to tumours (Enhertu).

---

## Value chains and production pipelines

### Industrial pipeline of mAb production (GMP / ICH Q5A)

```
┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Cell line (CHO)        │ ───> │ 2. Upstream bioreactor    │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Chromatography (Protein│ <─── │ 3. Harvest & clarification│
│    A + IEX) + viral safety│      │                           │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. UF/DF & formulation    │ ───> │ 6. Fill-finish & QC       │
└───────────────────────────┘      └───────────────────────────┘
```

#### Stage 1: Cell line
A stable CHO line with the target transgene is cloned and banked (MCB/WCB).

#### Stage 2: Upstream bioreactor
Fed-batch or perfusion in bioreactors reaches 2–10 g/L titer under PAT control.

#### Stage 3: Harvest & clarification
Centrifugation and depth filtration remove cells, yielding clarified liquor.

#### Stage 4: Chromatography & viral safety
Protein A → ion-exchange chromatography; viral inactivation and filtration (ICH Q5A).

#### Stage 5: UF/DF & formulation
Ultrafiltration/diafiltration concentrates the mAb and transfers it into formulation.

#### Stage 6: Fill-finish & QC
Sterile filling, lyophilisation (as needed), serialisation and batch release.